文献速递艾滋病与性传播感染

HIV感染孕妇妊娠期启动cART后免疫激活持续存在

Persistent Immune Activation in Human Immunodeficiency Virus-Infected Pregnant Women Starting Combination Antiretroviral Therapy After Conception.
PubMed 文献 · J Infect Dis · 2022-01-01

本研究在赞比亚HIV暴露未感染儿童队列中评估HIV及联合抗逆转录病毒治疗(cART)对妊娠期免疫激活的影响,比较HIV未感染、cART经治HIV感染及cART初治HIV感染孕妇的活化CD8+ T细胞。HIV感染/cART初治者免疫激活最高但妊娠期下降;妊娠期启动cART者免疫激活降低但未达HIV未感染者水平。母体免疫激活升高对婴儿健康与免疫的影响尚待确定。

要点

  • HIV感染/cART初治孕妇CD8+ T细胞免疫激活最高,妊娠期下降
  • 妊娠期启动cART可降低免疫激活,但未恢复至HIV未感染孕妇水平
  • 母体免疫激活升高对婴儿健康与免疫的影响尚不明确

核心结论

  • HIV感染孕妇即使妊娠期启动cART,免疫激活虽降低但未达到HIV未感染孕妇水平。

研究设计与样本

  • 赞比亚HIV暴露未感染儿童队列,随访自出生;比较HIV未感染(n=95)、cART经治HIV感染(n=111)和cART初治HIV感染(n=21)孕妇的活化CD8+ T细胞(CD38+和HLA-DR+)。

主要发现

  • HIV感染/cART初治孕妇免疫激活最高,但妊娠期下降。
  • 妊娠期启动cART的HIV感染孕妇免疫激活降低,但未降至与HIV未感染孕妇相似水平。

临床怎么用

  • 对妊娠期启动cART的HIV感染孕妇,应关注免疫激活持续存在及其对母婴结局的潜在影响。

局限性

  • 母体妊娠期免疫激活升高对后续婴儿健康与免疫的影响尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study evaluated the impact of human immunodeficiency virus (HIV) and combination antiretroviral therapy (cART) on immune activation during pregnancy in a Zambian cohort of HIV-exposed but uninfected children followed up from birth. Activated CD8+ T cells (CD38+ and HLA-DR+) were compared among HIV-uninfected (n = 95), cART experienced HIV-infected (n = 111), and cART-naive HIV-infected (n = 21) pregnant women. Immune activation was highest among HIV-infected/cART-naive women but decreased during pregnancy. Immune activation HIV-infected women who started cART during pregnancy was reduced but not to levels similar to those in HIV-uninfected women. The effects of elevated maternal immune activation in pregnancy on subsequent infant health and immunity remain to be determined.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Lohman-Payne B, Koster J, Gabriel B, et al. Persistent Immune Activation in Human Immunodeficiency Virus-Infected Pregnant Women Starting Combination Antiretroviral Therapy After Conception. J Infect Dis. 2022. PMID: 33780543. doi:10.1093/infdis/jiab095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。